- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01269515
Immunomodulating Therapy and Improved Vaccination Responses by Cox-2 Inhibitor in HIV-infected Patients (OUSCOX2)
Optional Immunomodulating Therapy and Improved Vaccination Responses by Adjuvant Administration of a Cyclooxygenase Type 2 Inhibitor in Antiretroviral naïve HIV-infected Patients and Patients on ART
Chronic immune activation is a central feature of HIV-infection, and the degree of activated T-cells is a better predictor of disease progression and mortality than plasma viral load. The study hypothesis is that the anti-inflammatory substance etoricoxib will dampen chronic immune activation and improve the effect of T-cell dependent vaccines in HIV-1 infected patients.
The aim of the present study is to explore the efficacy of the study drug on markers of immune activation and vaccine responses, as well as safety of the study drug, in HIV-infected patients not receiving antiretroviral therapy and in patients on long-term effective ART who had CD4 counts < 500.
Study Overview
Detailed Description
The current trial was based on our observations that augmented levels of cyclic adenosine monophosphate (cAMP) contribute to the T cell dysfunction in HIV-infected patients. In T cells, cAMP triggers a protein kinase A (PKA) - Csk - Lck inhibitory pathway that inhibits the proximal T cell receptor (TCR) signaling events. This mechanism may also be involved in the inhibitory function of regulatory T cells.
The investigators have hypothesized that elevated levels of cAMP in T cells from HIV-infected individuals result from increased production of prostaglandin E2 (PGE2) following activation-induced expression of cyclooxygenase type 2 (COX-2) in lymphoid tissues. Although the investigators have identified even COX-2 positive T cells in HIV-infected individuals, activated monocytes may be the major source of PGE2; high levels of COX-2 are produced de novo after a number of stimuli, particularly lipopolysaccharide (LPS). Circulating LPS is indeed increased in untreated chronic HIV infection due to enhanced translocation of microbial material and correlates to chronic immune activation and disease progression.
In three preceding clinical explorative trials, the investigators have demonstrated that COX-2 inhibition by COX-2 inhibitors (COX-2i) improves the immune functions of HIV patients, the first two studies included patients on antiretroviral treatment (ART). In the third trial the investigators also showed for the first time that treatment with a COX-2i was able to downregulate chronic immune activation and improve T cell functions (efficacy of T cell-dependent vaccine) in asymptomatic HIV-infected patients who did not use ART. In these patients, chronic immune activation was dampened as demonstrated; CD38 density on CD8+ T cells (primary endpoint) decreased by 24% by study week 12. This reduction could be extrapolated to a possible improvement of CD4+ T cell loss with 30 CD4 cells per ul per year with an approximate mean CD4 loss of 60 per ul per year. These data founded the basis for further support to this study through the GLOBVAC call program under the Norwegian Research Council (granted application for the current study).
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Oslo, Norway, 0407
- Department of Infectious Diseases, Oslo University Hospital
-
Oslo, Norway, 0407
- The Biotechnology Centre, University of Oslo
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
ART- group: Confirmed diagnosis of HIV infection < 8 years prestudy
- no HIV-related clinical manifestations including acute HIV infection
- no current indication or use for antiretroviral treatment
- CD4+ count > 350 x 10^6 /l
- HIV RNA > 2000 copies/ml
ART+ group: Confirmed diagnosis of HIV infection
- no HIV-related clinical manifestations including acute HIV infection
- On stabile effective antiretroviral treatment (HIV RNA <50 copies/ml)
- CD4+ count < 500 x 10^6 /l
- HIV RNA > 2000 copies/ml
Exclusion Criteria:
- concomitant or sporadic use of NSAID, corticosteroids or other immune modulating therapies including interferon-alpha
- cholesterol > 7 M
- under treatment for hypertension or antihypertensive treatment indicated at inclusion
- cardiovascular events or stroke in parents, siblings or off-springs occurring < 55 years of age
- elevated serum creatinine
- diabetes type I or II
- known hypersensitivity for etoricoxib, capsule substances or sulphonamides
- active peptic ulcer or gastrointestinal haemorrhage
- history of asthma, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria or other allergic reactions after taking acetyl salicylic acid or NSAID including COX-2 inhibitors
- pregnancy or insufficient birth control for females
- breastfeeding
- seriously deranged liver function
- creatine clearance < 30 ml/min
- inflammatory bowel disease
- heart failure (NYHA II-IV)
- established ischaemic heart disease, peripheral arteriosclerosis and/or cerebrovascular disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Etoricoxib 90 mg qd for 25 weeks ART-
Etoricoxib for 25 weeks.
Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 5 weeks.
|
90 mg QD
Other Names:
|
Active Comparator: Etoricoxib 90 mg qd for 2 weeks ART-
Etoricoxib for 2 weeks.
Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 1 week.
|
90 mg QD
Other Names:
|
No Intervention: Control ART-
No Etoricoxib.
Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 1 week.
|
|
Active Comparator: Etoricoxib 90 mg qd for 25 weeks ART+
Etoricoxib for 25 weeks.
Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 5 weeks.
|
90 mg QD
Other Names:
|
Active Comparator: Etoricoxib 90 mg qd for 2 weeks ART+
Etoricoxib for 2 weeks.
Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 1 week.
|
90 mg QD
Other Names:
|
No Intervention: Control ART+
No Etoricoxib.
Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 1 week.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in progression markers and vaccine responses within and between ART groups
Time Frame: After 6 months
|
Changes in CD38 density (CD38 molecules per CD38+CD8+CD3+ T cells) and in humoral and cellular immune responses to study-specific vaccines.
|
After 6 months
|
Serious adverse events
Time Frame: During the 6 months study period
|
Reductions of etoricoxib dose or stop of drug, adverse events including cardiovascular events, blood pressure, clinical chemistry.
|
During the 6 months study period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in HIV Gag CD8+ T cell responses within and between ART groups
Time Frame: 6 months
|
Changes in HIV Gag CD8+ T cell responses within and between ART groups
|
6 months
|
Changes in plasma markers of inflammation, coagulation and tryptophan metabolism within and between ART groups
Time Frame: 6 months
|
Changes in plasma markers of inflammation, coagulation and tryptophan metabolism
|
6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Dag Kvale, MD, PhD, Oslo University Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Cyclooxygenase 2 Inhibitors
- Etoricoxib
Other Study ID Numbers
- OUSCOX2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthNot yet recruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
CDC FoundationGilead SciencesUnknownHIV Preexposure Prophylaxis | HIV ChemoprophylaxisUnited States
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruiting
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Fenway Community Health; Tuberculosis...CompletedHIV/STI Risk | HIV/STI IncidenceUnited States, India
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
Hospital Clinic of BarcelonaCompletedIntegrase Inhibitors, HIV; HIV PROTEASE INHIBSpain
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingHIV Prevention | HIV Preexposure Prophylaxis | ImplementationKenya
Clinical Trials on Etoricoxib
-
Organon and CoCompleted
-
Organon and CoCompleted
-
Organon and CoCompleted
-
Organon and CoCompleted
-
Radboud University Medical CenterCompletedOssification, HeterotopicNetherlands
-
Organon and CoCompleted
-
Clinica Virgen MilagrosaMerck Sharp & Dohme LLCTerminatedSoft Tissue Injuries of the Shoulder | Tenosynovitis and Bursitis Affecting the ShoulderPeru
-
University of Erlangen-Nürnberg Medical SchoolMerck Sharp & Dohme LLC; Rush University Medical Center; HELIOS Kliniken GmbHTerminatedPain | Postoperative Pain | Osteoarthritis, HipGermany
-
Núcleo de Estudos em Esportes e Ortopedia, BrazilMerck Sharp & Dohme LLCUnknownSprains and Strains | ContusionsBrazil
-
Organon and CoCompletedAcute Pain Following a Total Abdominal Hysterectomy